<DOC>
	<DOCNO>NCT02152371</DOCNO>
	<brief_summary>The main purpose study evaluate use study drug know dulaglutide participant type II diabetes take once-daily insulin glargine . The study last 31 week participant .</brief_summary>
	<brief_title>A Study Dulaglutide ( LY2189265 ) Participants With Type II Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Have type 2 diabetes ( base World Health Organization 's [ WHO ] diagnostic criterion ) Have treat basal insulin glargine daily without metformin least 3 month prior screen Doses daily insulin glargine metformin ( take ) must stable 3month period prior screen . Doses metformin consider stable prescribed dos period range minimum require dose ( ≥1500 mg/day ) maximum approve dose per locallyapproved label Have HbA1c value ≥7.0 % ≤10.5 % assessed central laboratory screen Require insulin glargine dose increase week 3 per treattotarget ( TTT ) algorithm base SMPG data collect prior week Have stable weight ( ±5 % ) ≥3 month prior screen Have body mass index ( BMI ) ≤45 kilogram per square meter ( kg/m^2 ) screening Are able willing administer weekly randomize therapy Are females childbearing potential must : Test negative pregnancy screen , base serum pregnancy test Agree use reliable method birth control Not breastfeed Have treat ANY antihyperglycemia regimen , basal insulin glargine daily without metformin , within 3 month prior screen screen week 3 Have history ≥1 episode ketoacidosis hyperosmolar state/coma Have history hypoglycemia unawareness within 6 month prior screen Have treat drug promote weight loss within 3 month prior screen screen week 3 Are receive chronic ( &gt; 14 day ) systemic glucocorticoid therapy receive therapy within 4 week prior screen screen week 3 Have follow cardiovascular condition within 2 month prior screen : acute myocardial infarction ( MI ) , New York Heart Association ( NYHA ) Class III Class IV heart failure , cerebrovascular accident ( stroke ) Have know clinically significant gastric empty abnormality undergone gastric bypass surgery restrictive bariatric surgery Have acute chronic hepatitis , sign symptoms liver disease , alanine aminotransferase ( ALT ) level &gt; 2.5 time upper limit reference range , determined central laboratory Have history chronic pancreatitis acute idiopathic pancreatitis , diagnose type acute pancreatitis within 3 month prior screen Have estimate glomerular filtration rate ( eGFR ) &lt; 30 milliliters/minute/1.73 square meter ( mL/min/m^2 ) , calculate Chronic Kidney DiseaseEpidemiology ( CKDEPI ) equation , determined central laboratory ; participant metformin , renal disease renal dysfunction ( example , serum creatinine ≥1.5 mg/deciliter [ dL ] [ male ] ≥1.4 mg/dL [ female ] eGFR [ CKDEPI ] &lt; 60 mL/min/1.73 m^2 ) Have evidence significant , uncontrolled endocrine abnormality Have self family history type 2A type 2B multiple endocrine neoplasia ( MEN 2A 2B ) absence know Ccell hyperplasia Have self family history medullary Ccell hyperplasia , focal hyperplasia , carcinoma ( include sporadic , familial , part MEN 2A 2B syndrome ) Have serum calcitonin ≥20 picograms/mL , determined central laboratory Have evidence significant , active autoimmune abnormality Have condition list section contraindication use insulin glargine , , participant use metformin , condition contraindication use metformin would require metformin discontinuation per label Have history transplant organ Have history active untreated malignancy , remission clinically significant malignancy 5 year prior screen Have history condition , opinion investigator , may preclude participant follow complete protocol Have hematologic condition may interfere HbA1c measurement ( eg , hemolytic anemia , sicklecell disease )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>